Meta-Analysis of 66,000 Patients Finds Small Pancreatitis Risk With GLP-1 Drugs, No Clear Pancreatic Cancer Link | Research

The takeaway

A meta-analysis of 62 RCTs with 66,232 patients found GLP-1 receptor agonists carry a small overall pancreatitis risk (RR 1.44) that disappears when accounting for background medications, with no significant pancreatic cancer association.

RR 1.44 for pancreatitis (overall)
The small elevated risk became non-significant when stratified by background medication use, suggesting confounding rather than a true GLP-1 RA effect

What the researchers found

This meta-analysis of 62 RCTs involving 66,232 patients found a statistically significant but small increased risk of pancreatitis with GLP-1 receptor agonists overall (RR: 1.44, 95% CI 1.09-1.89, p=0.009). However, this significance disappeared when stratified by background medication use — neither the with-background-medication group (RR: 1.28) nor the without-background-medication group (RR: 1.37) reached significance alone.

For pancreatic cancer, no overall significant association was found (RR: 1.30, 95% CI 0.86-1.97). A significant association appeared only in the subgroup taking background medications (RR: 1.85, p=0.03), but not without them. The authors note this difference is likely minimal given that many excluded studies had zero events in both arms.

Why it matters

With over 66,000 patients analyzed from RCTs spanning seven GLP-1 RAs (including semaglutide, tirzepatide, and retatrutide), this is the most comprehensive meta-analysis of pancreatic safety for these blockbuster peptide drugs. The results provide substantial reassurance — any pancreatitis risk is small and likely confounded by background medications, and pancreatic cancer risk is not significantly elevated.

How the study worked

Systematic review and meta-analysis following PRISMA guidelines, searching PubMed, Embase, and Cochrane Library. 62 RCTs were included covering dulaglutide, exenatide, liraglutide, semaglutide, beinaglutide, retatrutide, and tirzepatide. Mean patient age was 58.3 years with mean follow-up of 43.5 weeks. Risk ratios were calculated with subgroup analysis stratified by background medication use.

Who was studied

66,232 patients across 62 RCTs; mean age 58.3 years; mean follow-up 43.5 weeks; drugs: dulaglutide, exenatide, liraglutide, semaglutide, beinaglutide, retatrutide, tirzepatide

What this study cannot tell us

Mean follow-up of 43.5 weeks may be insufficient to detect pancreatic cancer risk, which could require years of exposure. Many excluded studies had zero events in both arms, which could bias the analysis. Background medication confounding makes it difficult to isolate GLP-1 RA effects. The meta-analysis pools different GLP-1 RAs which may have different risk profiles.

How to read the evidence

This is a strong-grade systematic review and meta-analysis of 62 randomized controlled trials — the highest tier of clinical evidence. The large sample size (66,232 patients) provides substantial statistical power, and the PRISMA methodology ensures rigorous study selection.

When this study was published

Published in 2025, this is the most up-to-date meta-analysis on GLP-1 RA pancreatic safety, including newer agents like tirzepatide and retatrutide that were not covered in earlier reviews.

The bigger picture

This meta-analysis represents a major advancement from the conflicting evidence that existed a decade ago regarding GLP-1 RA pancreatic safety. With seven different drugs analyzed across 62 trials, it provides the strongest evidence to date that pancreatic risks from these peptide drugs are minimal. As GLP-1 RAs become some of the most prescribed medications worldwide, this level of safety evidence is critical for both prescribers and patients.

Questions still open

Would longer follow-up periods (5+ years) reveal a pancreatic cancer signal that the current mean 43.5-week follow-up cannot detect?
Do individual GLP-1 RAs (e.g., semaglutide vs. tirzepatide vs. retatrutide) differ in pancreatic risk, or is the class effect uniform?
What specific background medications confound the pancreatitis risk, and should prescribers account for these combinations?

Common questions

Should I worry about pancreatitis if I'm taking a GLP-1 drug like Ozempic or Mounjaro?

This large meta-analysis found only a small overall increase in pancreatitis risk (44% relative increase), which became non-significant when accounting for other medications. The absolute risk remains very low. However, if you experience severe abdominal pain, you should seek medical attention. Your doctor should be aware of this risk when prescribing.

Do GLP-1 drugs cause pancreatic cancer?

Based on this analysis of 66,232 patients across 62 clinical trials, there is no significant link between GLP-1 receptor agonists and pancreatic cancer. A small association appeared only in patients taking multiple background medications, and the authors consider this likely minimal. However, the average follow-up was less than a year, so longer-term monitoring continues.

Read the original research

Evaluating the Rates of Pancreatitis and Pancreatic Cancer Among GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of Randomised Controlled Trials.

Endocrinology, diabetes & metabolism, 8(5), e70113

View on PubMed ↗Publisher’s paper ↗

Citation

Wen, Jimmy; Nadora, Denise; Bernstein, Ethan; How-Volkman, Christiane; Truong, Alina; Joy, Bethany; Kou, Megan; Muttalib, Zohaer; Alam, Arsh; Frezza, Eldo. (2025). Evaluating the Rates of Pancreatitis and Pancreatic Cancer Among GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of Randomised Controlled Trials.. Endocrinology, diabetes & metabolism, 8(5), e70113. https://doi.org/10.1002/edm2.70113